All Terrain Financial Advisors, LLC Amgen Inc Transaction History

All Terrain Financial Advisors, LLC

$308 Million
Q3 2025

A detailed history of All Terrain Financial Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, All Terrain Financial Advisors, LLC holds 5,591 shares of AMGN stock, worth $1.91 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

5,591

Previous 7,002 20.15%

Holding current value

$1.91 Million

Previous $1.96 Million 19.34%

% of portfolio

0.51%

Previous 0.71%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$271.18 - $309.22 $382,634 - $436,309	-1,411 Reduced 20.15%	5,591 $1.58 Million
Q2 2025 Aug 12, 2025	BUY	$262.28 - $309.85 $786 - $929	3 Added 0.04%	7,002 $1.96 Million
Q1 2025 May 14, 2025	BUY	$258.59 - $327.36 $110,159 - $139,455	426 Added 6.48%	6,999 $2.18 Million
Q4 2024 Feb 13, 2025	BUY	$258.78 - $328.31 $49,685 - $63,035	192 Added 3.01%	6,573 $1.71 Million
Q3 2024 Nov 13, 2024	SELL	$309.38 - $337.38 $4,950 - $5,398	-16 Reduced 0.25%	6,381 $2.06 Million

Q2 2024 Aug 08, 2024	BUY	$262.75 - $319.31 $24,435 - $29,695	93 Added 1.48%	6,397 $2 Million
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $806 - $973	-3 Reduced 0.05%	6,304 $1.79 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $14,319 - $16,153	56 Added 0.9%	6,307 $1.82 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $12,463 - $15,473	57 Added 0.92%	6,251 $1.68 Million
Q2 2023 Aug 04, 2023	BUY	$214.27 - $253.37 $117,419 - $138,846	548 Added 9.71%	6,194 $1.38 Million
Q1 2023 May 12, 2023	BUY	$225.79 - $275.2 $9,934 - $12,108	44 Added 0.79%	5,646 $1.36 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $17,864 - $22,698	78 Added 1.41%	5,602 $1.47 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $4,713 - $5,316	21 Added 0.38%	5,524 $1.25 Million
Q2 2022 Aug 15, 2022	SELL	$230.71 - $256.74 $94,591 - $105,263	-410 Reduced 6.93%	5,503 $1.34 Million
Q1 2022 May 16, 2022	SELL	$219.27 - $242.57 $49,335 - $54,578	-225 Reduced 3.67%	5,913 $1.43 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $795 - $910	-4 Reduced 0.07%	6,138 $1.38 Million
Q3 2021 Nov 12, 2021	SELL	$212.27 - $248.7 $6,580 - $7,709	-31 Reduced 0.5%	6,142 $1.31 Million
Q2 2021 Aug 13, 2021	SELL	$233.58 - $259.14 $42,044 - $46,645	-180 Reduced 2.83%	6,173 $1.51 Million
Q1 2021 May 13, 2021	BUY	$221.91 - $258.6 $13,314 - $15,516	60 Added 0.95%	6,353 $1.58 Million
Q4 2020 Feb 08, 2021	BUY	$216.38 - $257.67 $82,008 - $97,656	379 Added 6.41%	6,293 $1.45 Million
Q3 2020 Nov 13, 2020	BUY	$234.65 - $260.95 $15,252 - $16,961	65 Added 1.11%	5,914 $1.5 Million
Q2 2020 Jul 28, 2020	SELL	$197.81 - $242.74 $36,594 - $44,906	-185 Reduced 3.07%	5,849 $1.38 Million
Q1 2020 May 14, 2020	SELL	$182.24 - $241.7 $2,004 - $2,658	-11 Reduced 0.18%	6,034 $1.22 Million
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $10,028 - $12,889	-53 Reduced 0.87%	6,045 $1.46 Million
Q3 2019 Nov 14, 2019	SELL	$174.11 - $208.62 $68,947 - $82,613	-396 Reduced 6.1%	6,098 $1.18 Million
Q2 2019 Aug 14, 2019	BUY	$166.7 - $195.41 $833 - $977	5 Added 0.08%	6,494 $1.2 Million
Q1 2019 May 14, 2019	SELL	$180.87 - $203.88 $48,834 - $55,047	-270 Reduced 3.99%	6,489 $1.23 Million
Q4 2018 Feb 15, 2019	BUY	$178.4 - $208.25 $3,389 - $3,956	19 Added 0.28%	6,759 $1.32 Million
Q3 2018 Nov 09, 2018	SELL	$185.29 - $208.89 $1,111 - $1,253	-6 Reduced 0.09%	6,740 $1.4 Million
Q2 2018 Aug 09, 2018	BUY	$166.05 - $186.51 $54,132 - $60,802	326 Added 5.08%	6,746 $1.25 Million
Q1 2018 May 15, 2018	BUY	$169.43 - $198.0 $26,261 - $30,690	155 Added 2.47%	6,420 $1.1 Million
Q4 2017 Feb 15, 2018	BUY	$168.79 - $188.59 $1.06 Million - $1.18 Million	6,265	6,265 $1.09 Million

Others Institutions Holding AMGN

# of Institutions

3,273

Shares Held

428M

Call Options Held

6.11M

Put Options Held

5.85M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $183B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of All Terrain Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on All Terrain Financial Advisors, LLC with notifications on news.

Account

All Terrain Financial Advisors, LLC Amgen Inc Transaction History